JAGSONPAL PHARMACEUTICALS LTD.

Jagsonpal Pharmaceuticals Ltd. has successfully consummated the acquisition of Group Pharmaceuticals Limited's Wellness Portfolio, effective October 01, 2026. This strategic move, following the fulfillment of conditions precedent under the Business Transfer Agreement (BTA), aims to bolster Jagsonpal's existing Rx franchise by adding a complementary portfolio. The acquisition is expected to create cross-selling opportunities through an expanded field force and doctor network, contributing to the company's ₹500 Cr ambition and enhancing overall productivity. This marks Jagsonpal's third acquisition in four years, building on previous integrations of Yash Pharma and Aequitas Healthcare, and is part of a strategy to build scale, expand market access, and create long-term shareholder value.

Jagsonpal Pharmaceuticals Limited has announced the closure of its trading window for designated persons and their immediate relatives. This closure is effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the quarter and six months ended September 30, 2026. The company will announce the date of the board meeting to approve these results in due course. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Jagsonpal Pharmaceuticals Limited has entered into a Business Transfer Agreement with Group Pharmaceuticals Limited to acquire its Wellness Portfolio for an initial consideration of ₹23.7 crores, with an additional consideration of up to ₹23.0 crores linked to FY 2027-28 sales, capped at a total of ₹46.7 crores. The acquisition, structured as a slump sale, is expected to be completed by November 1, 2026. This strategic move aims to strengthen Jagsonpal's pharmaceutical portfolio, expand its presence in relevant therapeutic segments, and enhance market reach. The acquired portfolio had a turnover of ₹24.6 Crores in FY 2025-26 and operates in the pharmaceutical industry.

Jagsonpal Pharmaceuticals Ltd. has entered into a Business Transfer Agreement with Group Pharmaceuticals Limited to acquire its Wellness Portfolio on a going-concern basis via slump sale. The acquisition, valued at an initial ₹23.7 crores with an additional consideration of up to ₹23.0 crores linked to FY 2027-28 sales (total cap ₹46.7 crores), is expected to be completed by November 1, 2026. This strategic move aims to strengthen Jagsonpal's pharmaceutical portfolio, enhance its presence in key therapeutic segments, and expand its market reach. The acquired portfolio had a turnover of ₹24.6 Crores in FY 2025-26 and operates in the pharmaceutical industry.

Jagsonpal Pharmaceuticals Limited has announced its 47th Annual General Meeting (AGM) will be held on Friday, September 18, 2026, at 03:30 P.M. via Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Annual Report for the Financial Year 2025-26, including the AGM notice, has been dispatched to members. The company has facilitated remote e-voting from September 14 to September 17, 2026, with a cut-off date of September 11, 2026. The report highlights a revenue of ₹2,872 million and operating PAT of ₹446 million for FY26, with a 7% revenue growth and 19% operating PAT growth. The company also completed a share buyback of ₹400 million and declared a 200% dividend.

Jagsonpal Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, forming part of the Annual Report, details the company's corporate identity, operations, employee data, and market reach. The company is primarily engaged in the marketing and distribution of pharmaceutical formulations, with exports contributing a small percentage of its turnover. As of the reporting date, the company has a subsidiary named Aequitas Healthcare Pvt Ltd.

Jagsonpal Pharmaceuticals Limited announced its annual report for FY 2025-26, detailing a revenue of ₹2,872 million and operating PAT of ₹446 million, with an operating EBITDA of ₹609 million. The company reported a 7% revenue growth and 19% operating PAT growth for the fiscal year. The 47th Annual General Meeting (AGM) is scheduled for September 18, 2026, to be held via Video Conferencing. The report also highlights a ₹400 million share buyback completed during the year and a declared 200% dividend, including a special dividend of 75%. The record date for dividend payment is September 04, 2026.

Jagsonpal Pharmaceuticals Ltd has issued letters to shareholders without registered email addresses, providing a web link to access the Annual Report for the financial year 2025-26 and the Notice of the 47th Annual General Meeting (AGM). The AGM is scheduled for September 18, 2026, via Video Conferencing. The Annual Report and AGM Notice are also being sent electronically to shareholders with registered email IDs. The company has complied with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by providing this access.

Jagsonpal Pharmaceuticals Ltd announced the designation of two new Senior Management Personnel: Mr. Balmukund Keshav as Deputy General Manager (Information Technology) and Mr. Sanjay Singhal as General Manager (CQA & Regulatory Affairs). These appointments are effective July 29, 2026, following an internal restructuring. Mr. Keshav brings over 29 years of IT leadership experience, while Mr. Singhal has 31 years of experience in the pharmaceutical industry, with expertise in manufacturing, supply chain, quality, and regulatory affairs. The company has provided detailed profiles and disclosures as per SEBI regulations.

Jagsonpal Pharmaceuticals Ltd has announced September 04, 2026, as the record date for determining shareholder entitlement to a proposed dividend of ₹4 per equity share (200%) for the financial year ended March 31, 2026. The dividend recommendation was made by the Board of Directors on April 27, 2026, and is subject to shareholder approval at the 47th Annual General Meeting (AGM) scheduled for September 18, 2026. The AGM will be conducted via Video Conferencing. If approved, the dividend will be paid within 30 days of declaration, after deducting applicable taxes.